Loading...
Loading...
MGTA| Name | Value |
|---|---|
| Revenues | 0.0K |
| Cost of Revenue | 0.0K |
| Gross Profit | 0.0K |
| Operating Expense | 5,457.0K |
| Operating I/L | -7,375.0K |
| Other Income/Expense | -1,918.0K |
| Interest Income | 4,091.0K |
| Pretax | -3,284.0K |
| Income Tax Expense | -6,009.0K |
| Net Income/Loss | -3,284.0K |
Magenta Therapeutics, Inc. is a clinical-stage biotechnology company specializing in developing medicines for patients with blood cancers, genetic diseases, and autoimmune diseases. The company's primary focus is on the development of MGTA-117, an anti-CD117 antibody targeting hematopoietic stem cells and genetically mutated stem cells associated with acute myeloid leukemia and myelodysplastic syndromes. Additionally, they are working on a CD45-antibody drug conjugate for potential use in autoimmune diseases and hematology-oncology transplants, as well as MGTA-145 for autologous and allogeneic transplants. Magenta Therapeutics also has a cell therapy program, E478, for stem cell-based gene therapy and genome editing.
